Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Appetite control toothpaste

This article was originally published in The Tan Sheet

Executive Summary

White Glo Crave Away toothpaste, which claims to "help suppress appetite and reduce food cravings" and whiten teeth, is expected to hit U.S. shelves by Aug. 1, Great White Trading Company announces April 17. An Herbal Whitening Toothpaste and Professional Choice Toothpaste also will be available under the brand in the U.S. this summer. According to the Santa Rosa, Calif.-based marketer, White Glo oral care products, which are developed by the Australian firm Barros Laboratories, are ranked third in market share in Australia and "are destined to be a recognized U.S. brand." Crave Away's homeopathic formula includes Nux Vomica 30X, which is "well known to help reduce cravings and the desire to over indulge by sending a signal to the brain indicating fullness," the firm states. The product also contains Fucus Vesiculosus 6X and Garcinia Quaesita 5X, an ingredient containing hydroxyl-citric acid (HCA) which may "help to control appetite and reduce the desire for carbohydrates," Great White adds. The SRP for a 5.2 oz tube is $5.99-$6.49...

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel